Recent Updates
Recently added Catalysts
INSM Positive Sentiment Score: 70/100

Insmed To Present at the BofA Securities 2025 Health Care Conference Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to...

Key Takeaway: Insmed Incorporated announced its participation at the BofA Securities 2025 Health Care Conference in Las Vegas on May 13, 2025. The event aims to highlight the company's advancements in biopharmaceutical therapies, particularly for serious diseases. Insmed is recognized for its diverse portfolio of approved and investigational medicines, with a focus on innovative approaches including gene therapy and AI-driven protein engineering. Additionally, Insmed has been recognized as a top employer in the industry.

Market Sentiment Analysis

POSITIVE FACTORS

  • Insmed is presenting at a notable industry conference, showcasing its commitment to innovation.
  • The company is advancing a diverse portfolio of investigational medicines.
  • Insmed has been recognized as one of the best employers in the biopharmaceutical industry.

Full Press Release Details

BRIDGEWATER, N.J. , April 29, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM ), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that management will present at the BofA Securities 2025 Health Care Conference in Las Vegas on Tuesday, May 13, 2025 , at 2:20 p.m. PT .
This event will be webcast live and can be accessed by visiting the investor relations section of the Company's website at www.insmed.com . Webcasts will be archived for a period of 30 days following the conclusion of the live events.
Insmed Incorporated is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. The Company is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines as well as cutting-edge drug discovery focused on serving patient communities where the need is greatest. Insmed's most advanced programs are in pulmonary and inflammatory conditions, including a therapy approved in the United States , Europe , and Japan to treat a chronic, debilitating lung disease. The Company's early-stage programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue.
Headquartered in Bridgewater, New Jersey , Insmed has offices and research locations throughout the United States , Europe , and Japan . Insmed is proud to be recognized as one of the best employers in the biopharmaceutical industry, including spending four consecutive years as the No. 1 Science Top Employer. Visit www.insmed.com to learn more.
Bryan Dunn Vice President, Investor Relations (646) 812-4030 [email protected]
Claire Mulhearn Vice President, Corporate Communications (862) 842-6819 [email protected]
SOURCE Insmed Incorporated

21 %

Frequently Asked Questions

When is Insmed's presentation at the BofA Conference?

Insmed will present at the BofA Conference on May 13, 2025, at 2:20 p.m. PT.

Where can I watch Insmed's conference presentation?

You can watch it live on Insmed's investor relations page at www.insmed.com.

What type of therapies does Insmed focus on?

Insmed focuses on first- and best-in-class therapies for serious diseases.

What locations does Insmed operate in?

Insmed has offices and research facilities in the U.S., Europe, and Japan.

What is Insmed's most advanced program category?

Insmed's advanced programs primarily target pulmonary and inflammatory conditions.

Last updated: Apr 29, 2025